JAZZ Price Prediction Next Week
Analysis and Insights
News and Event Impact:
Jazz Pharmaceuticals (JAZZ) has recently announced the acquisition of Chimerix for $935 million, enhancing its oncology portfolio. This strategic move is expected to positively impact the stock price as it strengthens JAZZ's position in the market. However, insider sentiment is negative, with 58 insiders selling shares, indicating potential concerns.
Technical Indicators:
- RSI: 51.45 (6-period) and 58.12 (12-period), indicating a neutral stance.
- MACD: Positive but showing a slight decline, suggesting weakening momentum.
- Bollinger Bands: The stock is near the lower band, indicating potential overselling.
Fibonacci Levels:
The stock is approaching a critical support level, which could act as a floor or lead to a breakdown.
Analyst Sentiment:
Mixed ratings with Buy from Stifel Nicolaus and Needham, but a Hold from Cantor Fitzgerald.
Price Prediction:
Given the acquisition news and technical indicators, JAZZ is expected to trade between $136 and $140 next week.
Recommendation:
Buy at the lower end of the range, considering the strategic acquisition and potential bounce from support levels. However, monitor insider activity and market sentiment closely.
JAZZ Similar Chart Price Prediction
The price of JAZZ is predicted to go up 2.05%, based on the high correlation periods with MSA. The similarity of these two price pattern on the periods is 98.17%.
JAZZ
MSA
Up: 2.05%Similarity: 98.17%
JAZZ Revenue Forecast
JAZZ EPS Forecast
JAZZ FAQs
What is JAZZ revenue forecast for next quarter？
What is JAZZ eps forecast for next quarter？
JAZZ VS S&P500
The GW acquisition allows Jazz to reach patient populations with rare and severe forms of epilepsy with approved indications for Epidiolex as young as 1 year of age.
Jazz's extensive network of sleep doctors should give the company a competitive edge when marketing its new sleep therapies.
Xyrem's historically strong cash generation has allowed the company to make recent acquisitions to help diversify its portfolio.
JAZZ Analyst's Forecast
Jeffrey Hung
Morgan Stanley
Buy
2025-03-07
Price Target
$175 → $183
Upside
+31.83%
Morgan Stanley analyst Sean Laaman assumed coverage of Jazz Pharmaceuticals with an Overweight rating and a price target of $183, up from $175. The firm model higher oxybate revenue than the Street consensus and "more meaningful potential" from Ziihera in first-line gastroesophageal adenocarcinoma, the analyst tells investors.
Ashwani Verma
UBS
Hold → Strong Buy
2025-03-07
Price Target
$145 → $179
Upside
+28.95%
Gregory Fraser
Truist Securities
Strong Buy
2025-03-06
Price Target
$220 → $230
Upside
+68.56%
